Literature DB >> 6464744

Neonatal screening for cystic fibrosis by dried blood spot trypsin assay. Results in 47 127 newborn infants from a homogeneous population.

A Cassio, F Bernardi, S Piazzi, M Capelli, E Frejaville, M P Villa, E Martelli, A Balsamo, S Salardi, R Merighi.   

Abstract

47 127 newborn infants from the Emilia-Romagna region were screened for cystic fibrosis by dried blood spot trypsin assay. In the initial 12 099 subjects screened with a non-standardized method, two children with cystic fibrosis were observed. Of the remaining 35 028 newborn infants, 299 showed high immunoreactive trypsin values; retesting revealed persistent elevation in 11. Sweat testing confirmed cystic fibrosis in 6 subjects and was normal in 5. Clinical monitoring of these 5 children has, as yet, shown no pathological signs. No false-negative test results have yet been identified. In our region, cystic fibrosis frequency would appear to be 1 case every 5 890 newborn infants. Our study confirms that elevated immunoreactive trypsin is characteristic of newborn infants with cystic fibrosis and that screening by determination of immunoreactive trypsin is of great benefit since it allows early diagnosis and a rational approach to therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6464744     DOI: 10.1111/j.1651-2227.1984.tb09970.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  3 in total

1.  Effects of newborn screening of cystic fibrosis on reported maternal behaviour.

Authors:  C Boland; N L Thompson
Journal:  Arch Dis Child       Date:  1990-11       Impact factor: 3.791

2.  Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis.

Authors:  E Ranieri; R G Ryall; C P Morris; P V Nelson; W F Carey; A C Pollard; E F Robertson
Journal:  BMJ       Date:  1991-05-25

3.  Nocturnal oximetry in infants with cystic fibrosis.

Authors:  M P Villa; J Pagani; V Lucidi; S Palamides; R Ronchetti
Journal:  Arch Dis Child       Date:  2001-01       Impact factor: 3.791

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.